QUINNsNextStep

Nektar Range for 3/2020

Long
NASDAQ:NKTR   Nektar Therapeutics
Earnings beat yesterday with positive mobility in R&D, plus the regulatory committee has resumed inquiries that were previously placed on hold.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.